Fig. 6

CPI-613 inhibits lipid metabolism through suppressing ACC activity in pancreatic cancer cells. a, b The effects of CPI-613 on lipid metabolism and glycolysis. AsPC-1 and PANC-1 cells were treated with or without 200 μM CPI-613 for 48 h, followed by Western blot with Glycolysis antibody sampler kit (a) and Fatty acid and lipid metabolism antibody sampler kit (b), respectively. c, d The effects of CPI-613 on the accumulation of lipid droplets determined by Oil-Red-O staining. The representative images and quantitative data from three independent experiments were shown in (c) and (d), respectively. e The effects of CPI-613 on released FAA levels evaluated by Free Fatty Acid Quantification Kit. **p < 0.01